BNTX – BioNTech SE
BioNTech SEBNTX
$95.20Name : BioNTech SE
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $22,891,358,208.00
EPSttm : -2.81
BioNTech SE
$95.20
0.08%$0.08Float Short %
2.37
Margin Of Safety %
Put/Call OI Ratio
0.84
EPS Next Q Diff
-1.89
EPS Last/This Y
-0.19
EPS This/Next Y
1.06
Price
95.19
Target Price
142.78
Analyst Recom
1.45
Performance Q
-6.86
Relative Volume
0.44
Beta
1.39
Ticker: BNTX
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-12-02 | BNTX | 96.04 | 0.89 | 1.07 | 43164 |
| 2025-12-03 | BNTX | 96.73 | 0.87 | 0.11 | 43247 |
| 2025-12-04 | BNTX | 95.52 | 0.85 | 1.16 | 43927 |
| 2025-12-05 | BNTX | 96.24 | 0.85 | 0.37 | 44426 |
| 2025-12-08 | BNTX | 97.26 | 0.85 | 0.67 | 44506 |
| 2025-12-09 | BNTX | 95.93 | 0.85 | 0.33 | 44574 |
| 2025-12-10 | BNTX | 95.65 | 0.84 | 0.78 | 45244 |
| 2025-12-11 | BNTX | 96.44 | 0.83 | 0.91 | 45862 |
| 2025-12-12 | BNTX | 94.78 | 0.83 | 0.12 | 46193 |
| 2025-12-15 | BNTX | 93.72 | 0.82 | 0.70 | 46450 |
| 2025-12-16 | BNTX | 92.18 | 0.82 | 1.78 | 46337 |
| 2025-12-17 | BNTX | 91.54 | 0.80 | 0.48 | 46701 |
| 2025-12-18 | BNTX | 91.4 | 0.80 | 1.02 | 46503 |
| 2025-12-19 | BNTX | 92.54 | 0.78 | 1.21 | 47238 |
| 2025-12-22 | BNTX | 92.19 | 0.96 | 0.44 | 33792 |
| 2025-12-23 | BNTX | 94.15 | 0.93 | 0.08 | 35081 |
| 2025-12-26 | BNTX | 94.51 | 0.84 | 1.39 | 40394 |
| 2025-12-29 | BNTX | 95.21 | 0.84 | 0.44 | 40590 |
| 2025-12-30 | BNTX | 95.19 | 0.84 | 1.97 | 40707 |
| 2025-12-31 | BNTX | 95.19 | 0.84 | 0.64 | 41123 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-12-02 | BNTX | 96.11 | -105.5 | -875.2 | -3.82 |
| 2025-12-03 | BNTX | 96.73 | -105.5 | -953.1 | -3.82 |
| 2025-12-04 | BNTX | 96.00 | -105.5 | -903.0 | -3.82 |
| 2025-12-05 | BNTX | 96.25 | -105.5 | -939.7 | -3.27 |
| 2025-12-08 | BNTX | 97.28 | -105.5 | - | -3.27 |
| 2025-12-09 | BNTX | 95.85 | -105.5 | -863.9 | -3.27 |
| 2025-12-10 | BNTX | 95.74 | -105.5 | -919.2 | -3.27 |
| 2025-12-11 | BNTX | 96.00 | -105.5 | -932.4 | -3.27 |
| 2025-12-12 | BNTX | 94.80 | -105.5 | -887.4 | -3.43 |
| 2025-12-15 | BNTX | 93.81 | -105.5 | -906.2 | -3.43 |
| 2025-12-16 | BNTX | 93.81 | -105.5 | -877.0 | -3.42 |
| 2025-12-17 | BNTX | 91.57 | -105.5 | -927.8 | -3.42 |
| 2025-12-18 | BNTX | 91.46 | -105.5 | -954.7 | -3.42 |
| 2025-12-19 | BNTX | 92.52 | -105.5 | -1018.0 | -3.42 |
| 2025-12-22 | BNTX | 92.32 | -105.5 | -905.4 | -3.42 |
| 2025-12-23 | BNTX | 94.00 | -105.5 | -1009.3 | -3.42 |
| 2025-12-26 | BNTX | 94.51 | -105.5 | -923.3 | -3.42 |
| 2025-12-29 | BNTX | 95.21 | -105.5 | -983.5 | -3.42 |
| 2025-12-30 | BNTX | 95.23 | -105.5 | -932.8 | -3.42 |
| 2025-12-31 | BNTX | 95.19 | -105.5 | -928.1 | -3.42 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-12-02 | BNTX | 0.00 | -2.43 | 2.52 |
| 2025-12-03 | BNTX | 0.00 | -2.43 | 2.52 |
| 2025-12-04 | BNTX | 0.00 | -2.43 | 2.52 |
| 2025-12-05 | BNTX | 0.00 | -2.43 | 2.52 |
| 2025-12-08 | BNTX | 0.00 | -2.44 | 2.52 |
| 2025-12-09 | BNTX | 0.00 | -2.44 | 2.52 |
| 2025-12-10 | BNTX | 0.00 | -2.44 | 2.52 |
| 2025-12-11 | BNTX | 0.00 | -2.44 | 2.52 |
| 2025-12-12 | BNTX | 0.00 | -2.44 | 2.52 |
| 2025-12-15 | BNTX | 0.00 | -2.33 | 2.52 |
| 2025-12-16 | BNTX | 0.00 | -2.33 | 2.52 |
| 2025-12-17 | BNTX | 0.00 | -2.33 | 2.52 |
| 2025-12-18 | BNTX | 0.00 | -2.33 | 2.52 |
| 2025-12-19 | BNTX | 0.00 | -2.33 | 2.52 |
| 2025-12-22 | BNTX | 0.00 | -2.33 | 2.52 |
| 2025-12-23 | BNTX | 0.00 | -2.33 | 2.52 |
| 2025-12-26 | BNTX | 0.00 | -2.33 | 2.37 |
| 2025-12-29 | BNTX | 0.00 | -2.33 | 2.37 |
| 2025-12-30 | BNTX | 0.00 | -2.33 | 2.37 |
| 2025-12-31 | BNTX | 0.00 | -2.33 | 2.37 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.14
Avg. EPS Est. Current Quarter
-0.06
Avg. EPS Est. Next Quarter
-2.03
Insider Transactions
Institutional Transactions
-2.33
Beta
1.39
Average Sales Estimate Current Quarter
823
Average Sales Estimate Next Quarter
219
Fair Value
Quality Score
56
Growth Score
33
Sentiment Score
85
Actual DrawDown %
79.5
Max Drawdown 5-Year %
-82.2
Target Price
142.78
P/E
Forward P/E
PEG
P/S
6.48
P/B
1.05
P/Free Cash Flow
EPS
-2.63
Average EPS Est. Cur. Y
-3.42
EPS Next Y. (Est.)
-2.35
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-17.92
Relative Volume
0.44
Return on Equity vs Sector %
-30.4
Return on Equity vs Industry %
-15
EPS 1 7Days Diff
-0.1
EPS 1 30Days Diff
0.19
EBIT Estimation
-928.1
BioNTech SESector: Healthcare
Industry: Biotechnology
Employees: 6772
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany. The company develops BNT111, which is in Phase 2 clinical trial for advance melanoma; BNT113, which is in Phase 2 clinical trial to treat head and neck squamous cell carcinoma; BNT116, which is in Phase I clinical trial for non-small cell lung cancer; BNT142, which is in phase 1/2 clinical trial for multiple solid tumors; BNT151, which is in phase 1/2 clinical trial for solid tumors; BNT152+BNT153, which is in phase 1 clinical trial for solid tumors; and BNT122/RO7198457, which is in Phase 2 clinical trial to treat adjuvant high-risk muscle-invasive urothelial carcinoma, colorectal cancer, pancreatic ductal adenocarcinoma, advance melanoma, as well as in phase 1a/1b clinical trial for advanced/metastatic solid tumors. It also develops BNT211, which is in phase 1 clinical trial to treat CLDN6+ solid tumors; BNT221, phase 1 clinical trial for the treatment of cancer; BNT311/GEN1046 (acasunlimab), which is in phase 3 clinical trial for solid tumors; BNT312/GEN1042, which is in phase 1/2 and 1 clinical trial to treat solid tumors; BNT314/GEN1059, which is in Phase 1/2 clinical trial for advanced or metastatic solid tumors; BNT315/GEN1055, which is in phase 1/2 clinical trial for advanced solid tumors; BNT317, which is in phase 1 clinical trial for advanced solid tumors; BNT327, which is in phase 1/2, 2, and 3 clinical trial to treat small cell lung cancer, advanced/metastatic tnbc, neuroendocrine neoplasm, malignant mesothelioma, EGFR-mutant non-squamous, hepatocellular carcinoma, and advanced solid tumors; and BNT316/ONC-392, which is in phase 1/2, 2, and 3 clinical trial to treat metastatic, non-small cell lung cancer, platinum-resistant ovarian cancer, metastatic castration resistant prostate cancer, and advanced or metastatic solid tumor. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.
stock quote shares BNTX – BioNTech SE Stock Price stock today
news today BNTX – BioNTech SE stock forecast ,stock prediction 2023 2024 2025
marketwatch BNTX – BioNTech SE yahoo finance google finance
stock history BNTX – BioNTech SE invest stock market
stock prices BNTX premarket after hours
ticker BNTX fair value insiders trading